Professor Johann de Bono is Head of the Division of Clinical Studies at the ICR and an international expert in the development of molecularly targeted cancer therapies against prostate cancer.

He leads the Drug Development Unit – one of the world’s largest phase I clinical trials units for cancer, run jointly between the ICR and The Royal Marsden. Professor de Bono has also led on multiple phase III trials that have changed the standard of care for prostate cancer, including trials of the ICR-discovered drug abiraterone, plus cabazitaxel and enzalutamide.

Most recently he has been involved in leading studies that have mapped the molecular landscape of lethal prostate cancer, and shown how circulating biomarkers could be used for managing patients with the disease. He has also helped lead research showing that PARP inhibitors have impressive anti-tumour activity against some prostate cancers.

Professor de Bono's full bio

Professor de Bono's key publications

Professor Charlotte Bevan is Professor of Cancer Biology and leads the Prostate Cancer Research Programme in the Department of Surgery and Cancer at Imperial College London. Her research focuses on improving therapy prospects for men with advanced prostate cancer with specific interests in, the mechanisms of androgen signalling leading to prostate cancer growth, the activation and downstream consequences of androgen response, the identification of other key biological molecules involved in the androgen response, the emergence of resistance to hormonal control of prostate tumours, and the identification of new approaches to inhibit androgen receptor pathways once current hormonal therapies fail and of biomarkers to better target therapies to patients.

In addition, a major aspect of Professor Bevan’s role is the training and mentoring of young scientists and medical students at every level.

Professor Charlotte Bevan's full biography is available here

Further information about Professor Charlotte Bevan's lab is available here

Professor Mark Emberton is a Professor of Interventional Oncology at University College London and a Clinical Director at the Royal College of Surgeons of England. His principal interests lie in trying to improve diagnostic and therapeutic pathways for men with prostate cancer, principally through the use of novel imaging techniques and minimally invasive treatments. He is the principal investigator in a number of studies in this area.

Professor Mark Emberton's full biography is available here

Until January 2018, Dr Gerhardt Attard was a Cancer Research UK Clinician Scientist at the ICR and Consultant Medical Oncologist at The Royal Marsden. His main research interest is the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC).

Dr Attard is an experienced clinical trialist in CRPC and is a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer.

Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Dr Attard sits on a number of advisory boards and the editorial board of Annals of Oncology as an associate editor.

Dr Attard's full bio

Dr Gerhardt key publications

Professor Robert Brown is Professor of Translational Oncology at Imperial College London, where he heads the Epigenetics Unit and is Head of the Division of Cancer. He also has a joint appointment at the ICR.

Professor Brown investigates epigenetics and drug resistance, with a particular focus on ovarian and prostate cancer. He examines how tumours acquire resistance to chemotherapy with the goal of improving treatment by overcoming drug resistance. He has developed a number of biomarkers of epigenetic events that are being used in early clinical trials.

Professor Robert Brown's full biography is available here

Professor David Dearnaley is Professor of Uro-Oncology at the ICR and Honorary Consultant Clinical Oncologist at The Royal Marsden. He has been central to the development of intensity-modulated radiotherapy – a radiotherapy technique that reduces damage to healthy tissue – and is currently running several trials for treating prostate and testicular cancer with more directed radiotherapy, including the investigation of new image-guided radiotherapy techniques.

Professor David Dearnaley's full biography is available here

Professor Rosalind Eeles is a Professor of Oncogenetics at the ICR and Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden.

Professor Eeles is a leading expert in the field of cancer genetics and runs a research programme at the ICR on genetic predisposition to prostate cancer and management of individuals with BRCA mutations. She leads several large international consortia conducting research into genetic predisposition to prostate cancer and its clinical application and has authored more than 350 original publications.

Professor Eeles is a Fellow of the Royal College of Physicians of London, Fellow of the Royal College of Radiologists (Clinical Oncology Faculty), and Fellow of the Academy of Medical Sciences, UK.

Professor Rosalind Eeles' full biography is available here

Professor Rosalind Eeles' key publication are available here

Dr Emma Hall is Deputy Director (Research) of the Cancer Research UK-funded Clinical Trials and Statistics Unit (ICR-CTSU). Dr Emma Hall is a medical statistician with a particular interest in clinical trials that aim to maximise the treatment of urological, and head and neck cancers. She sits on a number of independent data monitoring committees for national phase II and III trials. Dr Hall is the lead statistician overseeing the CHHiP and TOPARP trials.

Dr Emma Hall's full biography is available here

Dr Chris Parker is a Consultant Clinical Oncologist at The Royal Marsden . 

He is chief investigator of multiple prostate cancer trials which test the use of active surveillance for localised disease, post-operative radiotherapy for locally advanced disease and of radium-223 for bone metastases. He led the radium-223 registration phase III trial. Dr Parker is Chair of the National Cancer Research Institute Prostate Cancer Clinical Studies Group and a member of the Department of Health Prostate Cancer Advisory Group.

Dr Chris Parker's full biography is available here

Dr Chris Parker's key publications are available here

Dr Amanda Swain leads the Development and Cancer Team within the Division of Cancer Biology at the ICR. She studies how organs such as the prostate, gonads and adrenal gland form normally, and the role that these processes have in cancer development and progression. Dr Swain has a major interest in WNT signalling in prostate cancer.  As well as running her own research team, Dr Swain is head of the ICR’s Tumour Profiling Unit.

Dr Amanda Swain's full biography is available here